Berotralstat: A promising oral treatment for hereditary angioedema with normal C1-inhibitor

FHS
June 8, 2024
11:56 am

BioCryst Pharmaceuticals, Inc. today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily berotralstat.

Afib Guidelines Add New Stages, Upgrade Catheter Ablation

A new staged framework for atrial fibrillation (Afib) classification was proposed in updated U.S. guidelines. Afib catheter ablation gained a broader class I recommendation from

December 1, 2023

UK doctors turn to AI chatbots for diagnoses and documentation, but are they putting patient privacy at risk?

A recent survey found that 20% of UK general practitioners use AI chatbots in clinical practice, helping with documentation, diagnoses, and patient management. However, concerns

September 26, 2024

Two Noninvasive Ventilation Modes Win for Riskiest NICU Newborns

The known advantages of certain noninvasive respiratory support techniques prevailed for extremely preterm newborns following extubation and for those with more severe respiratory failure, subgroup

July 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.